Puli Pharmaceutical has won a cooperation agreement worth RMB one hundred million for multi specific

On January fourteen, two thousand twenty-five, Puli Pharmaceutical achieved a good start by successfully signing a cooperation agreement worth RMB one hundred million for multi specification products of iodiparol in Argentina. This not only expands Puli Pharmaceutical's market in Argentina, but also marks a solid step forward in its internationalization strategy in the field of contrast agents. This cooperation marks the first time that Puli Pharmaceutical has achieved results in the Latin American market. Previously, Puli Pharmaceutical's iodiparol injection had successfully signed orders worth over one hundred million yuan in the US market. With excellent product quality and stable supply, Puli Pharmaceutical has won the trust of American customers and established a good reputation internationally. The signing of this cooperation agreement in Argentina further confirms the competitiveness and influence of Puli Pharmaceutical in the international contrast agent market. one. Argentine pharmaceutical market Argentina is the third largest economy in Latin America, after Brazil and Mexico. In Argentina, health expenditure accounts for about nine% -ten% of GDP, which is one of the highest levels in the region. A two thousand twenty-one assessment report on the health security capabilities of one hundred and ninety-five countries worldwide, produced by the Johns Hopkins Center for Health Safety, Nuclear Threat Organization, and The Economist Intelligence Unit, pointed out that Latin American countries such as Argentina have more robust and abundant health systems compared to the world average. This will also benefit the development of the biopharmaceutical industry. The two thousand twenty-one Health Security Index of Major Latin American Countries (data sources: Johns Hopkins University Center for Health Security, Nuclear Threat Organization, and The Economist Intelligence Unit, two thousand twenty-two) shows that China has maintained its position as the second largest trading partner in Latin America for ten consecutive years. Currently, it is also the second largest trading partner of Argentina (after Brazil) and the largest source of imports for Argentina. In February two thousand twenty-two, Argentina officially joined the "the Belt and Road" initiative. China and Argentina have signed a currency swap agreement worth one hundred and thirty billion yuan. Since April two thousand twenty-four, Argentina has been allowed to use the Chinese yuan for import trade settlement with China. Previously, the market layout of Puli Pharmaceuticals in Latin America was relatively weak. This cooperation with central enterprises to actively expand the international market in Argentina not only responded to the call for high-quality development of the "the Belt and Road", but also was an important step in the international strategic deployment of Puli Pharmaceuticals. Puli Pharmaceutical hopes to take this as an opportunity, starting from Argentina, to fully tap into the Latin American pharmaceutical market, achieve broader market coverage and deeper development. two European and American GMP standards, comprehensive specifications, and integrated raw material preparation. Iopamidol injection is widely used as a contrast agent in the field of medical imaging, mainly for diagnostic procedures such as CT scanning and angiography. Thanks to its production line meeting the GMP standards of Europe and America, as well as the integrated supply chain advantages of eleven specifications of iodoprolol injection products and raw material formulations, Puli Pharmaceutical has successfully won the favor of Argentine customers. The Argentine drug regulatory authorities recognize the US GMP or European GMP, and the production line of Puli Pharmaceutical complies with the GMP requirements of the US, EU, and China, fully meeting the cooperation requirements. Puli Pharmaceutical has developed a total of eleven specifications of iodoprolol injection, which are different from the original